Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration

AIM: Providing intravitreal ranibizumab therapy for neovascular age related macular degeneration (nARMD) is a source of increasing strain for many UK eye departments. Whilst most units attempt to adhere to the product licence of following up patients at four weekly intervals; delays in follow up app...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Gwyn Samuel, Seow, Eulee, Evans, Huw, Owoniyi, Muyiwa, Evans, Sam, Blyth, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487938/
https://www.ncbi.nlm.nih.gov/pubmed/26155076
http://dx.doi.org/10.1016/j.sjopt.2015.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487938/
https://www.ncbi.nlm.nih.gov/pubmed/26155076
http://dx.doi.org/10.1016/j.sjopt.2015.02.004

Ejemplares similares